Background and objective: Despite its clinical and prognostic significance, few studies have evaluated the severity of exertional oxygen desaturation in fibrotic interstitial lung disease (ILD). Our objectives were to identify clinical and physiological variables that predict the extent of exertional oxygen desaturation in fibrotic ILD and to quantify the severity of desaturation compared to chronic obstructive pulmonary disease (COPD). Methods: This retrospective study compared the results of 6-min walk test (6MWT) performed while breathing room air in fibrotic ILD patients and COPD patients eligible for pulmonary rehabilitation. Outcomes included the oxygen saturation (SpO 2 ) nadir and the change in SpO 2 from rest during a 6MWT. Predictor variables were identified on unadjusted analysis, followed by multivariate analysis to identify independent predictors of desaturation. Results: The study included 134 patients with fibrotic ILD and 274 patients with COPD. The ILD and COPD cohorts had similar age, sex, frequency of major comorbidities, walk distance, baseline SpO 2 and baseline Borg dyspnoea scores. DL CO was the strongest predictor of desaturation in both cohorts. Compared to patients with COPD, ILD patients had significantly lower SpO 2 nadir values (88.1 AE 6.4 vs 91.0 AE 4.6) and greater decrease in SpO 2 from baseline (7.4 AE 5.2 vs 4.5 AE 3.7) after adjusting for demographic features and pulmonary physiology (P < 0.0005), with greater between-group differences at lower DL CO values. Conclusion: Patients with fibrotic ILD have greater oxygen desaturation during 6MWT compared to patients with COPD when adjusting for demographic features and pulmonary physiology. These findings suggest the need for disease-specific studies to evaluate the potential utility of ambulatory oxygen in fibrotic ILD.
INTRODUCTION
Interstitial lung disease (ILD) is a diverse group of entities that cause damage to the lung parenchyma through varying degrees of inflammation and fibrosis. Fibrotic ILDs result in restrictive ventilatory physiology and impaired gas exchange, frequently leading to exertional hypoxemia and functional limitation. The clinical and prognostic importance of exertional hypoxemia is well established, with multiple studies demonstrating a strong correlation of exertional desaturation with dyspnoea and mortality. [1] [2] [3] [4] [5] [6] Despite its importance, few studies have evaluated the severity, predictors and management of exertional oxygen desaturation in fibrotic ILD.
Chronic obstructive pulmonary disease (COPD) is a common condition typically caused by cigarette smoking that results in a chronic inflammatory response involving the airways and lung parenchyma. 7 COPD is characterized by persistent and progressive airflow limitation as well as impaired gas exchange that leads to dyspnoea and functional limitation. Despite similar features of dyspnoea and functional limitation in both ILD and COPD, the extent of exertional hypoxemia is often profound in patients with advanced ILD and may be more severe than in COPD. The objectives of this study were to: (i) identify clinical and physiological variables
SUMMARY AT A GLANCE
Few studies have evaluated the severity of exertional hypoxemia in fibrotic interstitial lung disease (ILD). We demonstrate that exertional hypoxemia is more common and severe in fibrotic ILD compared to COPD. More ILD-specific studies are needed to evaluate the potential utility of ambulatory oxygen in fibrotic ILD.
that predict the severity of exertional oxygen desaturation in fibrotic ILD and COPD and (ii) compare the severity of exertional oxygen desaturation in fibrotic ILD and COPD. Our pre-specified hypothesis was that exertional oxygen desaturation would be more severe in ILD than in COPD with adjustment for pulmonary physiology.
METHODS

Study design and study population
This retrospective study compared the results of 6-min walk test (6MWT) and walking oximetry data in a convenience cohort of patients with fibrotic ILD and those with COPD (UBC Research Ethics Board H16-00472). Patients with fibrotic ILD or COPD were eligible if they had performed a walk test during a pulmonary rehabilitation screening assessment or as part of an ILD clinic assessment between July 2000 and May 2016. The ILD cohort included patients with ILD subtypes that are not typically accompanied by extrapulmonary consequences of the underlying disease. Specific diagnoses included idiopathic pulmonary fibrosis, 8 idiopathic fibrotic non-specific interstitial pneumonia, 9 chronic hypersensitivity pneumonitis, 10 unclassifiable ILD, 11 desquamative interstitial pneumonia, 9 drug-induced ILD and asbestosis. Patients were excluded if they (i) required oxygen supplementation at rest or during the walk test, (ii) had participated in a pulmonary rehabilitation program in the preceding 6 months, (iii) had combined pulmonary fibrosis and emphysema or (iv) had other extrapulmonary disease, or functional limitation that could impair either exercise capacity or oxygenation.
Walk tests
Walk tests were performed according to recommended guidelines. 12, 13 Patients performed one of two tests-a 6MWT or walking oximetry-depending on whether the test was being performed for disease monitoring or for measuring exertional oxygen desaturation as a criterion for ambulatory oxygen supplementation. Oxygen saturation (SpO 2 ) and heart rate were recorded at regular 30-s or 60-s intervals, while blood pressure and the modified Borg dyspnoea scale were documented before and after the walk test. 14 The stopping criteria applied during each of the walk tests followed local health authority's clinical practice standards and procedures based on the ATS Pulmonary Function Laboratory Management and Procedure Manual. 15 In terms of SpO 2 saturation, walk tests were continued until 6 min elapsed or SpO 2 measured by pulse oximetry dropped below 80% and was sustained for at least 1 min or continued to fall. The % predicted walk distance was calculated as previously described. 16 The end-exercise SpO 2 , SpO 2 nadir, delta SpO 2 (change from baseline to nadir) and mean SpO 2 was determined for each 6MWT. A poor pulse oximetry signal resulted in 1.6% of the total data points being imputed based on the mean SpO 2 taken from recorded values immediately before and after the missing data point. A detailed description of our walk test procedures is provided in Appendix S1 (Supplementary Information).
Additional measurements
Patient characteristics were obtained from the clinical record, including age, height, mass, comorbidities and medications. Pulmonary function test (PFT) results were obtained from the clinical record. PFTs were performed in accordance with standard recommendations, including forced vital capacity (FVC), forced expiratory volume in 1 s (FEV 1 ), ratio of FEV 1 to FVC, total lung capacity (TLC), residual volume (RV) and diffusion capacity of the lung for carbon monoxide (DL CO ). [17] [18] [19] All included PFTs were completed within 12 months of the analysed walk test and the majority were completed on the same visit or within 3 months.
Statistical analysis
Data are presented as mean (SD) or number (%). Characteristics of the ILD and COPD cohorts were compared using a chi-square test, t-test or Wilcoxon rank sum test, as appropriate. Spearman correlation coefficients were used to determine the association of potential predictor variables with nadir and change in SpO 2 . Predictor variables with P < 0.10 on bivariate analysis were entered into a stepwise multivariate regression analysis with backward elimination. A two-sided P value <0.05 was considered significant for all analyses. Data were analysed using Stata SE v11.0 (StataCorp, College Station, TX, USA).
RESULTS
Patient characteristics
The study population included 134 patients with ILD and 274 patients with COPD ( Table 1) . The ILD and COPD cohorts had similar age, sex and frequency of major comorbidities. ILD patients had a higher body mass index, were less likely to have smoked and had accumulated fewer pack-years compared to those patients with COPD. The ILD cohort had a higher FEV 1 and FEV 1 /FVC ratio and a lower TLC, RV and DL CO compared to the COPD cohort, corresponding to mildto-moderate severity in ILD and moderately-severe COPD. Patients with ILD and COPD had similar walk distance (meters and % predicted), baseline SpO 2 and baseline Borg dyspnoea score (Table 2) . A walking oximetry was performed instead of a 6MWT in 35 patients from the ILD cohort. Findings were unchanged for all comparisons when these patients were excluded and both types of tests were therefore pooled for all analyses.
Oxygen desaturation in patients with ILD
Mean 6-min walk distance (6MWD) in ILD was 360 m, with decline in SpO 2 from 95.5 to 88.9% during the test (Fig. 1) . The mean nadir SpO 2 was 88.1% (SD 6.4%, range 65-100%). A SpO 2 nadir ≤ 88% occurred in 65 ILD patients (49%), and 101 patients (75%) had a decline in SpO 2 ≥ 4% from baseline. Nine ILD patients (7% of the ILD cohort) did not complete the 6MWT due to hypoxemia stopping criteria. On unadjusted analysis, SpO 2 nadir and change in SpO 2 were associated with FEV 1 , FVC, TLC, RV, DL CO , walk distance (actual and % predicted) and SpO 2 at baseline (Table 3 , Fig. 2 ). DL CO and baseline SpO 2 were independent predictors of SpO 2 nadir on adjusted analysis, and DL CO was the only independent predictor of change in SpO 2 (Table 3) .
Oxygen desaturation in patients with COPD
Mean 6MWD in COPD was 363 m, with decline in SpO 2 from 95.5 to 92.3% during the test (Fig. 1) . The mean 
- † ILD diagnoses included idiopathic pulmonary fibrosis (n = 56), unclassifiable ILD (n = 52), chronic hypersensitivity pneumonitis (n = 19), idiopathic fibrotic non-specific interstitial pneumonia (n = 3), desquamate interstitial pneumonia (n = 2), drug-induced ILD (n = 1) and asbestosis (n = 1).
‡ P Value determined by Wilcoxon rank sum test. § Included asthma, sleep-disordered breathing and bronchiectasis. COPD, chronic obstructive pulmonary disease; DL CO , diffusion capacity of the lung for carbon monoxide; FEV 1 , forced expiratory volume in 1 s; FVC, forced vital capacity; GAP, Gender-Age-Physiology; GOLD, Global Initiative for Chronic Obstructive Lung Disease; ILD, interstitial lung disease; RV, residual volume; TLC, total lung capacity. Fig. 2 ). FEV 1 /FVC and DL CO were independent predictors of change in SpO 2 on adjusted analysis (Table 4) .
Comparison of desaturation in ILD and COPD
There was no difference in walk distance (actual P = 0.83, % predicted P = 0.64) or Borg dyspnoea score (P = 0.81) at the end of the 6MWT comparing patients with ILD and those with COPD ( Table 2 ). Compared to patients with COPD, ILD patients had a lower nadir, end-of-test and mean SpO 2 during 6MWT, as well as a larger decline in SpO 2 from baseline ( Fig. 1) . Patients Figure 1 Mean SpO 2 during 6-min walk test in ILD and COPD. *P < 0.05 for comparison of SpO 2 in ILD versus COPD patients. COPD, chronic obstructive pulmonary disease; ILD, interstitial lung disease; SpO 2 , oxygen saturation determined by pulse oximetry. with ILD had a 3.2% lower SpO 2 nadir compared to patients with COPD after adjusting for other predictors of SpO 2 nadir in the combined cohort (P < 0.0005). Additional independent predictors of SpO 2 nadir in the combined cohort included FEV 1 , DL CO and baseline SpO 2 (P < 0.005 for all variables). A diagnosis of ILD was associated with a 3.4% greater decline in SpO 2 during 6MWT compared to patients with COPD after adjusting for other predictors (P < 0.0005). Additional independent predictors of change in SpO 2 in the combined cohort included FEV 1 (P < 0.005), DL CO (P < 0.005) and having a secondary pulmonary comorbidity (P = 0.04). There was no difference in findings with adjustment for walk distance or restriction of the cohort to patients performing the test at the regional referral centre.
DISCUSSION
Previous studies of oxygen supplementation have primarily focused on COPD, with clinical trial results often extrapolated to other chronic respiratory diseases. [20] [21] [22] Our study demonstrates that exertional hypoxemia is more common and more severe in fibrotic ILD compared to COPD independent of lung function abnormalities, and that a low DL CO is the predominant predictor of oxygen desaturation in both diseases. The significant differences in exertional SpO 2 in ILD compared to COPD raise concerns regarding the appropriateness of generalizing COPD-derived evidence to patients with ILD and indicate the need for diseasespecific data. We showed that patients with fibrotic ILD have lower SpO 2 nadir as well as a greater decline in SpO 2 during 6MWT compared to patients with COPD. We adjusted for differences in multiple clinical variables in an attempt to standardize these comparisons for disease severity and other potential confounders. We also adjusted for walk distance to account for any potential difference in exercise intensity between the two cohorts and analysed subgroups of patients who were provided different instructions on walking speed. These analyses confirm the robustness of our findings, although the physiological explanation for differences across the two diseases remains unclear. Exertional hypoxemia is frequently associated with pulmonary vascular disease; however, we did not have sufficient echocardiographic data to determine the impact of pulmonary hypertension on the between-group differences in oxygenation. Furthermore, we do not have measures of pulmonary hypertension during exertion, which may be a more accurate predictor of exertional hypoxemia than pulmonary arterial pressure estimates obtained at rest. Future studies are needed to more fully evaluate the physiological basis for exertional hypoxemia in patients with fibrotic ILD, and to compare exercise physiology in ILD and COPD.
Previous trials have demonstrated a mortality benefit from continuous (≥15 h per day) long-term oxygen supplementation in patients with COPD and moderate resting hypoxemia. 20, 21 Given the absence of direct data, these results have been extrapolated to support the use of oxygen therapy in patients with other forms of chronic lung disease, with regional oxygen supplementation criteria typically not distinguishing between diseases. The role of oxygen supplementation exclusively in the ambulatory setting is more controversial. COPD patients with significant exertional oxygen desaturation on 6MWT have worse prognosis compared to patients with similar disease severity who do not experience exertional hypoxemia. 23 This finding provided justification for evaluation of ambulatory oxygen supplementation in patients with COPD; however, a recent randomized trial found no benefit of ambulatory oxygen on mortality or quality of life in COPD patients with isolated exertional desaturation. 22 It is unknown whether a similar lack of benefit to ambulatory oxygen supplementation would also be found in patients with ILD, particularly considering the more severe hypoxemia these patients experience compared to those with COPD. A low DL CO was the most significant predictor of exertional hypoxemia in both fibrotic ILD and COPD, with an association that changed across the spectrum of disease severity. At near-normal DL CO values, patients with fibrotic ILD and those with COPD had similar extents of exertional hypoxemia; however, ILD patients had more severe exertional hypoxemia than COPD patients for a given DL CO at lower DL CO values. Exertional hypoxemia was also associated with obstructive physiology in patients with COPD, as measured by the FEV 1 /FVC ratio. These findings are similar to predictors of dyspnoea in both diseases; DL CO strongly correlates with dyspnoea in fibrotic ILD, 1,2,24 while dyspnoea severity in COPD is related to measures of obstructive physiology such as dynamic hyperinflation. [25] [26] [27] Despite the differing impact of ventilatory physiology on hypoxemia and dyspnoea in these two conditions, there appears to be a preservation of the relationship between inspiratory neural drive and exertional dyspnoea in both ILD and COPD. 28 Research regarding the complex mechanisms behind dyspnoea in both diseases is ongoing.
We confirmed our pre-specified hypothesis that exertional oxygen desaturation would be more severe in ILD than in COPD after adjustment for pulmonary function, although future studies should be performed to elaborate on our findings. Additional studies are also required to determine whether these findings apply to patients who are ineligible for pulmonary rehabilitation, patients with more severe disease, or patients who require oxygen supplementation at rest or with ambulation. Lastly, there remains a need for mechanistic studies that would provide a more detailed physiological explanation for the differences across lung diseases. These studies would ideally measure arterial SpO 2 directly (i.e. using an arterial line); however, our pulse oximetry data instead has greater applicability to the clinical setting given the more frequent use of pulse oximetry when evaluating the need for ambulatory oxygen.
In summary, we have shown that exertional hypoxemia is more common and more severe in fibrotic ILD compared to COPD for a given level of lung function, and that a low DL CO is the strongest predictor of oxygen desaturation in both diseases. The differences in hypoxemia in fibrotic ILD compared to COPD suggest that studies on exertional hypoxemia in patients with COPD may not be generalizable to ILD, and that ILD-specific clinical trials are needed. Further research is required to evaluate the impact of oxygen supplementation for outpatients not meeting criteria for continuous oxygen supplementation, as well as for patients participating in supervised exercise programs. 29 Future studies are also needed to provide direct evidence on which ILD patients benefit from supplemental oxygen, and what criteria should be used to guide this therapy.
